Dec 12 (Reuters) - Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

The company's worst days might be behind it.

Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

By Rishika Sadam HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug ...

A medical expert warned of the side effects of the newly launched weight loss drug Ozempic.

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...